

prepared aqueous solutions, and the polyoxyethylene-polyoxypropylene glycols within the above-mentioned constituent ranges may gelate at around body temperature, i.e. about 37°C at a concentration of about 10-90% in its aqueous solution. As the most preferable example, there is prepared the polyoxyethylene-polyoxypropylene glycol block polymer aqueous solution of 15-30% concentration having a molecular weight of polypropylene glycol of 3,850 and a ethylene oxide content of 70% (Pluronic F-127).--

*page 9, rewrite the third full paragraph as follows  
first amf*

IN THE CLAIMS:

*claim 2 amended*

Claim 14 (twice amended) A cartilage and bone morphogenetic repairing composition comprising a collagen-free aqueous solution of a polyoxyethylene-polyoxypropylene glycol and an effective amount of a bone morphogenetic protein, the molecular weight of polypropylene glycol as a constituent of said polyoxyethylene-polyoxypropylene glycol is 900 to 4000 and the ethylene oxide content is 5 to 95% by weight of the polyoxyethylene-polyoxypropylene glycol molecule whereby the solution is aqueous at 1 to 30°C and gelatinizes at about 37°C.

*claim 15 (amended)*

REMARKS

The present amendment is being submitted in order to go back to the original terminology since the undersigned had misinterpreted the disclosure.

The specification has been amended to conform it as originally submitted and claim 14 has been amended to correct an error in order to change polyoxypropylene glycol back to polypropylene glycol.

Favorable reconsideration of the application is requested in view of the remarks submitted in the amendment of June 29, 2001 which are not being repeated in order to avoid unduly burdening the record.

Respectfully submitted,  
Bierman, Muserlian and Lucas

By: Charles A. Muserlian #19,683  
Attorney for Applicants  
Tel.# (212) 661-8000

CAM:ds  
Enclosures

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Charles A. Muserlian

July 27, 2001